- Home
- GOSS vs FORR Comparison
GOSS vs FORR Comparison
Compare GOSS & FORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | FORR |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 106.6M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GOSS | FORR |
|---|---|---|
| Price | $0.40 | $5.95 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 26.2M | 149.1K |
| Earning Date | 03-17-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $203.01 | $1.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $4.91 |
| 52 Week High | $3.87 | $11.57 |
Technical Indicators
Market Signals| Indicator | GOSS | FORR |
|---|---|---|
| Relative Strength Index (RSI) | 23.42 | 40.45 |
| Support Level | $0.33 | $5.02 |
| Resistance Level | $0.60 | $6.26 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 0.00 | 31.05 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.